come out next week for sure. Takeda probably wanted some lead time prior to the PR, and amln must surely have the figures available for both pram/lep and dav at the present time, they will be highly scrutinized by Takeda prior to a joint announcement.

In two weeks time we should see what the mono/label update bodes for byetta scripts, and again, IMHO, byetta scripts should make a noticeable surge, now that the pancreatic issue has been put to bed, and amln has clarafied the bogus renal situation.

All in all, I think that the next two-three weeks are going to give a very clear indication of amln's momentum, and we can all put these years of turmoil behind us!

Regards: War